Article
Ifebemtinib plus garsorasib as first-line treatment for KRASG12C-mutated non-small-cell lung cancer in China: a multicentre, single-arm expansion cohort from a phase 1b/2 trial.
The Lancet. Respiratory medicine - 1 Sept 2026
Song Zhengbo, Li Xingya, Lin Rongbo, Shi Huaqiu, Yuan Yuan, Liu Ying, Luo Yongzhong, Lv Tangfeng, Zhang Yiping, Zhu Liming, Zhu Yinxin, Zhang Ling, Wang Zaiqi
Abstract excerpt
BACKGROUND: Ifebemtinib, a potent selective oral inhibitor of FAK, has shown preclinical synergistic activity with KRASG12C inhibitors. Garsorasib is a novel KRASG12C inhibitor approved in China for patients with KRASG12C-mutated non-small-cell lung cancer (NSCLC). This study aimed to evaluate the safety and efficacy of ifebemtinib plus garsorasib in KRASG12C-mutated solid tumours. METHODS: This multicentre study...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.